<HashMap><database>biostudies-literature</database><scores/><additional><omics_type>Unknown</omics_type><volume>603(7899)</volume><submitter>Domizio JD</submitter><pubmed_abstract>COVID-19, which is caused by infection with SARS-CoV-2, is characterized by lung pathology and extrapulmonary complications&lt;sup>1,2&lt;/sup>. Type I interferons (IFNs) have an essential role in the pathogenesis of COVID-19 (refs &lt;sup>3-5&lt;/sup>). Although rapid induction of type I IFNs limits virus propagation, a sustained increase in the levels of type I IFNs in the late phase of the infection is associated with aberrant inflammation and poor clinical outcome&lt;sup>5-17&lt;/sup>. Here we show that the cyclic GMP-AMP synthase (cGAS)-stimulator of interferon genes (STING) pathway, which controls immunity to cytosolic DNA, is a critical driver of aberrant type I IFN responses in COVID-19 (ref. &lt;sup>18&lt;/sup>). Profiling COVID-19 skin manifestations, we uncover a STING-dependent type I IFN signature th</pubmed_abstract><journal>Nature</journal><pagination>145-151</pagination><full_dataset_link>https://www.ebi.ac.uk/biostudies/studies/S-EPMC8891013</full_dataset_link><repository>biostudies-literature</repository><pubmed_title>The cGAS-STING pathway drives type I IFN immunopathology in COVID-19.</pubmed_title><pmcid>PMC8891013</pmcid><pubmed_authors>de Leval L</pubmed_authors><pubmed_authors>Nass T</pubmed_authors><pubmed_authors>Garnier CV</pubmed_authors><pubmed_authors>Thacker VV</pubmed_authors><pubmed_authors>Berezowska S</pubmed_authors><pubmed_authors>Domizio JD</pubmed_authors><pubmed_authors>Schaller M</pubmed_authors><pubmed_authors>Guenova E</pubmed_authors><pubmed_authors>Gulen MF</pubmed_authors><pubmed_authors>Sharma K</pubmed_authors><pubmed_authors>Ablasser A</pubmed_authors><pubmed_authors>Yatim A</pubmed_authors><pubmed_authors>Dubois A</pubmed_authors><pubmed_authors>Goepfert C</pubmed_authors><pubmed_authors>Saidoune F</pubmed_authors><pubmed_authors>Gilliet M</pubmed_authors><pubmed_authors>Conrad C</pubmed_authors></additional><is_claimable>false</is_claimable><name>The cGAS-STING pathway drives type I IFN immunopathology in COVID-19.</name><description>COVID-19, which is caused by infection with SARS-CoV-2, is characterized by lung pathology and extrapulmonary complications&lt;sup>1,2&lt;/sup>. Type I interferons (IFNs) have an essential role in the pathogenesis of COVID-19 (refs &lt;sup>3-5&lt;/sup>). Although rapid induction of type I IFNs limits virus propagation, a sustained increase in the levels of type I IFNs in the late phase of the infection is associated with aberrant inflammation and poor clinical outcome&lt;sup>5-17&lt;/sup>. Here we show that the cyclic GMP-AMP synthase (cGAS)-stimulator of interferon genes (STING) pathway, which controls immunity to cytosolic DNA, is a critical driver of aberrant type I IFN responses in COVID-19 (ref. &lt;sup>18&lt;/sup>). Profiling COVID-19 skin manifestations, we uncover a STING-dependent type I IFN signature th</description><dates><release>2022-01-01T00:00:00Z</release><publication>2022 Mar</publication><modification>2025-04-04T19:58:12.332Z</modification><creation>2025-04-04T19:58:12.332Z</creation></dates><accession>S-EPMC8891013</accession><cross_references><pubmed>35045565</pubmed><doi>10.1038/s41586-022-04421-w</doi></cross_references></HashMap>